Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 118-126

  Shao, Kun ^a   Huang, Rongqin ^a   Li, Jianfeng ^a   Han, Liang ^a   Ye, Liya ^b   Lou, Jinning ^b   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Angiopep 2; Brain targeting; LRP; P glycoprotein; Polymeric micelles

Indexed keywords

AMPHOTERICIN B; ANGIOPEP-2; ANTIFUNGAL DRUGS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; DEOXYCHOLATE; DRUG CARRIER; DRUG DELIVERY SYSTEM; DRUG-TARGETING; ENTRAPPING EFFICIENCY; FUNGAL INFECTION; IN-VITRO; LOW DENSITY LIPOPROTEINS; LRP; MAMMALIAN CELLS; MODIFIED PE; P-GLYCOPROTEIN; POLYMERIC MICELLE; TRANSCYTOSIS; WATERSOLUBLE;

DRUG DELIVERY; GLYCOPROTEINS; MAMMALS; MICELLES; PROTEINS;

POLYMERS;

1, 2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(MACROGOL 2000); AMPHOTERICIN B DEOXYCHOLATE; ANGIOPEP 2; DRUG CARRIER; GLYCOPROTEIN P; MACROGOL; POLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN TISSUE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAMMAL CELL; MICELLE; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

AMPHOTERICIN B; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CELL SURVIVAL; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRUG COMPOUNDING; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ERYTHROCYTES; HEMOLYSIS; MALE; MICE; MICE, INBRED ICR; MICELLES; MICROSCOPY, ATOMIC FORCE; PARTICLE SIZE; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SHEEP; TISSUE DISTRIBUTION;

EID: 79951945021     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.018     Document Type: Article

References (57)

1. Davis J.A., Costello D.J., Venna N. Laboratory investigation of fungal infections of the central nervous system. Neurol. India 2007, 55(3):233-240.
2. Eric Searls D., Sico J.J., Bulent Omay S., Bannykh S., Kuohung V., Baehring J. Unusual presentations of nervous system infection by Cryptococcus neoformans. Clin. Neurol. Neurosurg. 2009, 111(7):638-642.
3. Glick J.A., Graham R.S., Voils S.A. Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. Ann. Pharmacother. 2010, 44(1):215-218.
4. Clemons K.V., Espiritu M., Parmar R., Stevents D.A. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 2005, 49(12):4867-4875.
5. Czub J., Borowski E., Baginski M. Interactions of amphotericin B derivatives with lipid membranes-a molecular dynamics study. Biochim. Biophys. Acta 2007, 1768(10):2616-2626.
6. Girois S.B., Chapuis F., Decullier E., Revol B.G. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 2005, 24(2):119-130.
7. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30years of clinical experience. Rev. Infect. Dis. 1990, 12(2):308-329.
8. Ruhnke M., Kofla G., Otto K., Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007, 21(8):659-676.
9. Groll A.H., Giri N., Petraitis V., Petraitiene R., Candelario M., Bacher J.S., Piscitelli S.C., Walsh T.J. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 2000, 182(1):274-282.
10. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., Dasbach E.J., Platt R. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 2001, 32(5):686-693.
11. Vakil R., Kwon G.S. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 2006, 22(23):9723-9729.
12. Krishnadas A., Rubinstein I., Onyüksel H. Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for water-insoluble drugs. Pharm. Res. 2003, 20(2):297-302.
13. Onyüksel H., Ikezaki H., Patel M., Gao X.P., Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 1999, 16(1):155-160.
14. Ashok B., Arleth L., Hjelm R.P., Rubinstein I., Onyüksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J. Pharm. Sci. 2004, 93(10):2476-2487.
15. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. J. Control. Release 2005, 109(1-3):169-188.
16. Kabanov A.V., Slepnev V.I., Kuznetsova L.E., Batrakova E.V., Alakhov V.Yu., Melik-Nubarov N.S., Sveshnikov P.G., Kabanov V.A. Pluronic micelles as a tool for low-molecular compound vector delivery into a cell: effect of Staphylococcus aureus enterotoxin B on cell loading with micelle incorporated fluorescent dye. Biochem. Int. 1992, 26(6):1035-1042.
17. Lukyanov A.N., Torchilin V.P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug. Deliv. Rev. 2004, 56(9):1273-1289.
18. Demeule M., Régina A., Ché C., Poirier J., Nguyen T., Gabathuler R., Castaigne J.P., Béliveau R. Identification and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 2008, 324(3):1064-1072.
19. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 2000, 106(12):1489-1499.
20. Ito S., Ohtsuki S., Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier. Neurosci. Res. 2006, 56(3):246-252.
21. May P., Herz J., Bock H.H. Molecular mechanisms of lipoprotein receptor signaling. Cell. Mol. Life Sci. 2005, 62(19-20):2325-2338.
22. Demeule M., Currie J.C., Bertrand Y., Ché C., Nguyen T., Régina A., Gabathuler R., Castaigne J.P., Béliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 2008, 106(4):1534-1544.
23. Ke W., Shao K., Huang R., Han L., Liu Y., Li J., Kuang Y., Ye L., Lou J., Jiang C. Gene delivery targeted to the brain using an angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimers. Biomaterials 2009, 30(36):6976-6985.
24. Lou J.N., Gasche Y., Zhang L., Critico B., Monso-Hinard C., Juillard P., Morel P., Buurman W.A., Grau G.E. Differential reactivity of brain microvascular endothelial cells to TNF reflects the genetic susceptibility to cerebral malaria. Eur. J. Immunol. 1998, 28:3989-4000.
25. Xie Y., Ye L.Y., Zhang X.B., Hou X.P., Lou J.N. Establishment of an in vitro model of brain-blood barrier. Beijing Da Xue Xue Bao 2004, 36(4):435-438.
26. Vakil R., Kwon G.S. Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles. Mol. Pharm. 2008, 5(1):98-104.
27. Musacchio T., Laquintana V., Latrofa A., Trapani G., Torchilin V.P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol. Pharm. 2009, 6(2):468-479.
28. Hamed E., Sakr A. Application of multiple response optimization technique to extended release formulations design. J. Control. Release 2001, 73(2-3):329-338.
29. Mandal U., Gowda V., Ghosh A., Selvan S., Solomon S., Pal T.K. Formulation and optimization of sustained release matrix tablet of metformin HCl 500mg using response surface methodology. Yakugaku Zasshi 2007, 127(8):1281-1290.
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
31. Jung S.H., Lim D.H., Jung S.H., Lee J.E., Jeong K.S., Seong H., Shin B.C. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur. J. Pharm. Sci. 2009, 37(3-4):313-320.
32. Bang J.Y., Song C.E., Kim C., Park W.D., Cho K.R., Kim P.I., Lee S.R., Chung W.T., Choi K.C. Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)/dextran graft copolymer. Arch. Pharm. Res. 2008, 31(11):1463-1469.
33. Torchilin V.P. Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv. 2005, 2(4):319-327.
34. Torrado J.J., Espada R., Ballesteros M.P., Torrado-Santiago S. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 2008, 97(7):2405-2425.
35. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Nat. Acad. Sci. U.S.A. 2003, 100(10):6039-6044.
36. Sawant R.R., Sawant R.M., Torchilin V.P. Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur. J. Pharm. Biopharm. 2008, 70(1):51-57.
37. Taratula O., Garbuzenko O.B., Kirkpatrick P., Pandya I., Savla R., Pozharov V.P., He H., Minko T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 2009, 140(3):284-293.
38. Oh J.K., Tang C., Gao H., Tsarevsky N.V., Matyjaszewski K. Inverse miniemulsion ATRP: a new method for synthesis and functionalization of well-defined water-soluble/cross-linked polymeric particles. J. Am. Chem. Soc. 2006, 128(16):5578-5584.
39. Koziara J.M., Lockman P.R., Allen D.D., Mumper R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 2003, 20(11):1772-1778.
40. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47(1):65-81.
41. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 1999, 16(10):1564-1569.
42. Nazer B., Hong S., Selkoe D.J. LRP promotes endocytosis and degradation, but not transcytosis, of the amyloid-beta peptide in a blood-brain barrier in vitro model. Neurobiol. Dis. 2008, 30(1):94-102.
43. Régina A., Demeule M., Ché C., Lavallée I., Poirier J., Gabathuler R., Béliveau R., Castaigne J.P. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector angiopep-2. Br. J. Pharmacol. 2008, 155(2):185-197.
44. Vogelsinger H., Weiler S., Djanani A., Kountchev J., Bellmann-Weiler R., Wiedermann C.J., Bellmann R. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother. 2006, 57(6):1153-1160.
45. Christiansen K.J., Bernard E.M., Gold J.W., Armstrong D. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 1985, 152(5):1037-1043.
46. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 2009, 1788(10):2259-2266.
47. Siegal T., Horowitz A., Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J. Neurosurg. 1995, 83(6):1029-1037.
48. Papagiannaros A., Kale A., Levchenko T.S., Mongayt D., Hartner W.C., Torchilin V.P. Near infrared planar tumor imaging and quantification using nanosized Alexa 750-labled phospholipid micelles. Int. J. Nanomedicine 2009, 4:123-131.
49. Miller D.W., Batrakova E.V., Waltner T.O., Alakhov V.Yu., Kabanov A.V. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug. Chem. 1997, 8(5):649-657.
50. Hegmann E.J., Bauer H.C., Kerbel R.S. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 1992, 52(24):6969-6975.
51. Fontaine M., Elmquist W.F., Miller D.W. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci. 1996, 59(18):1521-1531.
52. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97(11):2517-2524.
53. Dabholkar R.D., Sawant R.M., Mongayt D.A., Devarajan P.V., Torchilin V.P. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm. 2006, 315(1-2):148-157.
54. Bolard J., Legrand P., Heitz F., Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 1991, 30(23):5707-5715.
55. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 1996, 9(4):512-531.
56. Lavasanifar A., Samuel J., Sattari S., Kwon G.S. Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharm. Res. 2002, 19(4):418-422.
57. Adler-Moore J., Proffitt R.T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 2002, 49:21-30.